Vital Therapies Hosting Analyst R&D Day Today

SAN DIEGO, May 24, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day today beginning at 11:00 a.m. Eastern Time

Presentations will focus on the disease state of severe alcoholic hepatitis (sAH) and ELAD’s proposed mechanism of action.  Presenting from Vital Therapies will be Russell J. Cox, Chief Executive Officer; Robert A. Ashley, M.A., Executive Vice President and Chief Technical Officer; Patricia W. Bedard, PhD, Director, Research Cell Biology and Dr. Jan Stange, Chief Medical Officer. 

In addition to members of the Vital Therapies team, two external clinical experts in the field of alcoholic hepatitis will be presenting: Dr. Stephen R. Atkinson, Specialist Registrar in Gastroenterology and Hepatology and an Honorary Clinical Lecturer at Imperial College London, and Dr. Nikolaos T. Pyrsopoulos of Rutgers New Jersey Medical School.

The live event will be accessible through the Investor Relations section of the Company’s website at http://ir.vitaltherapies.com/.  Individuals interested in participating via telephone should dial (855) 765-5682 (U.S. and Canada) or (919) 825-3204 (international) using conference ID number 4297749.

The event will be available for replay via telephone beginning today at approximately 4:00 p.m. Eastern Time, running through 4:00 p.m. Eastern Time on May 31, 2018. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 4297749. The archived webcast will be available on Vital Therapies’ website beginning approximately four hours after the live webcast has completed.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure.  The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials.  Vital Therapies, Inc. is based in San Diego, California.  Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Contact:
Vital Therapies, Inc. 
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
akildani@vitaltherapies.com

 

Primary Logo

Source: Vital Therapies, Inc.

* Page content (in order of occurrence in the default page.html.twig): * - node: Fully loaded node, if there is an automatically-loaded node * associated with the page and the node ID is the second argument in the * page's path (e.g. node/12345 and node/12345/revisions, but not * comment/reply/12345). * * Regions: * - page.header: Items for the header region. * - page.help: Dynamic help text, mostly for admin pages. * - page.content: The main content of the current page. * - page.sidebar_first: Items for the first sidebar. * - page.sidebar_last: Items for the second sidebar. * - page.footer: Items for the footer region. * * @see template_preprocess_page() * @see html.html.twig */ #}

Vital Therapies Hosting Analyst R&D Day Today

SAN DIEGO, May 24, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day today beginning at 11:00 a.m. Eastern Time

Presentations will focus on the disease state of severe alcoholic hepatitis (sAH) and ELAD’s proposed mechanism of action.  Presenting from Vital Therapies will be Russell J. Cox, Chief Executive Officer; Robert A. Ashley, M.A., Executive Vice President and Chief Technical Officer; Patricia W. Bedard, PhD, Director, Research Cell Biology and Dr. Jan Stange, Chief Medical Officer. 

In addition to members of the Vital Therapies team, two external clinical experts in the field of alcoholic hepatitis will be presenting: Dr. Stephen R. Atkinson, Specialist Registrar in Gastroenterology and Hepatology and an Honorary Clinical Lecturer at Imperial College London, and Dr. Nikolaos T. Pyrsopoulos of Rutgers New Jersey Medical School.

The live event will be accessible through the Investor Relations section of the Company’s website at http://ir.vitaltherapies.com/.  Individuals interested in participating via telephone should dial (855) 765-5682 (U.S. and Canada) or (919) 825-3204 (international) using conference ID number 4297749.

The event will be available for replay via telephone beginning today at approximately 4:00 p.m. Eastern Time, running through 4:00 p.m. Eastern Time on May 31, 2018. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 4297749. The archived webcast will be available on Vital Therapies’ website beginning approximately four hours after the live webcast has completed.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure.  The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials.  Vital Therapies, Inc. is based in San Diego, California.  Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Contact:
Vital Therapies, Inc. 
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
akildani@vitaltherapies.com

 

Primary Logo

Source: Vital Therapies, Inc.